Substance / Medication

Dolasetron

Overview

Active Ingredient
dolasetron
RxNorm CUI
68091

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

97 trials linked to this intervention

97
Total Trials
10
Recruiting
18
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia.
Vergne-Salle Pascale, Dufauret-Lombard Carine, Bonnet Christine et al. · Eur J Pain · 2011
PMID: 21036635RCT
[Dolasetron and shivering. A prospective randomized placebo-controlled pharmaco-economic evaluation].
Bock M, Bauer M, Rösler L et al. · Anaesthesist · 2007
PMID: 17021884RCT
Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.
Li Susie Xiujiang, Pequignot Edward, Panebianco Deborah et al. · J Clin Pharmacol · 2006
PMID: 16809805RCT
Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval.
Obal Detlef, Yang Dongsheng, Sessler Daniel I · Mayo Clin Proc · 2014
PMID: 24388024Observational
Optimization of sample pretreatment methods for simultaneous determination of dolasetron and hydrodolasetron in human plasma by HPLC-ESI-MS.
Hu Yuming, Chen Shuo, Chen Jitao et al. · J Chromatogr Sci · 2012
PMID: 22645289Observational
The addition of dexamethasone to dolasetron or haloperidol for treatment of established postoperative nausea and vomiting.
Rüsch D, Arndt C, Martin H et al. · Anaesthesia · 2007
PMID: 17635430Observational
Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.
Janicki Piotr K, Schuler H Gregg, Jarzembowski Tomasz M et al. · Anesth Analg · 2006
PMID: 16551910Observational
Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol.
Breyer-Pfaff U, Nill K · J Pharm Pharmacol · 2004
PMID: 15563768Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dolasetron (substance)
SNOMED CT
372488002
UMLS CUI
C0209210
RxNorm CUI
68091

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
97
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.